Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure
| Autor: | Michael J. Pollard, Catherine F. Notarius, Shin-ichi Ando, Beth L. Abramson, Toshihiko Kubo, Peter Picton, Deborah J. Atchison, John S. Floras |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Cardiomyopathy Dilated Male medicine.medical_specialty Sympathetic nervous system Cardiac output Sympathetic Nervous System Physiology Vasodilator Agents Cardiac Output Low Hemodynamics Angiotensin-Converting Enzyme Inhibitors Nitroglycerin Atrial natriuretic peptide Heart Rate Internal medicine Heart rate Internal Medicine Medicine Humans biology business.industry Dilated cardiomyopathy Angiotensin-converting enzyme Middle Aged medicine.disease Endocrinology medicine.anatomical_structure Heart failure biology.protein Cardiology and Cardiovascular Medicine business Atrial Natriuretic Factor circulatory and respiratory physiology |
| Zdroj: | Journal of hypertension. 19(3 Pt 2) |
| ISSN: | 0263-6352 |
| Popis: | Objectives Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described. Design and methods Heart rate and MSNA were recorded in 10 men (aged 39 ± 3 years, mean ± SE) with dilated cardiomyopathy (mean EF 20 ± 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 μg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis. Results ANP had no effect on HRV, but increased MSNA LF (from 7.9 ± 1.5 to 12.1 ± 2.6 U 2 ; P< 0.02) and total spectral power (from 47.9 ± 5.4 to 61.9 ± 6.8 U 2 ; P< 0.05). NTG had no effect on the variability of MSNA or HRV. Conclusions In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|